ARWR PE Ratio & Valuation, Is ARWR Overvalued

Historical Valuation

Arrowhead Pharmaceuticals Inc (ARWR) is now in the Fair zone, suggesting that its current forward PS ratio of 22.22 is considered Fairly compared with the five-year average of -21.66. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 45.62 to 102.09 according to relative valuation method.

Relative Value

Fair Zone

45.62-102.09

Current Price：60.67

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Arrowhead Pharmaceuticals Inc (ARWR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Arrowhead Pharmaceuticals Inc (ARWR) has a current Price-to-Book (P/B) ratio of 19.74. Compared to its 3-year average P/B ratio of 12.28, the current P/B ratio is approximately 60.73% higher. Relative to its 5-year average P/B ratio of 12.50, the current P/B ratio is about 57.92% higher. Arrowhead Pharmaceuticals Inc (ARWR) has a Forward Free Cash Flow (FCF) yield of approximately 1.70%. Compared to its 3-year average FCF yield of -12.02%, the current FCF yield is approximately -114.17% lower. Relative to its 5-year average FCF yield of -7.32%, the current FCF yield is about -123.26% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ARWR competitors is 36.90, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR.O) exhibits a P/S ratio of 22.22, which is -39.78% above the industry average. Given its robust revenue growth of 10461.32%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ARWR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ARWR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ARWR currently overvalued or undervalued?

What is Arrowhead Pharmaceuticals Inc (ARWR) fair value?

ARWR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 45.62 to 102.09 according to relative valuation method.

How does ARWR's valuation metrics compare to the industry average?

The average P/S ratio for ARWR's competitors is 36.90, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR) exhibits a P/S ratio of 22.22, which is -39.78% above the industry average. Given its robust revenue growth of 10461.32%, this premium appears sustainable.

What is the current P/B ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Mar 10 2026?

As of Mar 10 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a P/B ratio of 19.74. This indicates that the market values ARWR at 19.74 times its book value.

What is the current FCF Yield for Arrowhead Pharmaceuticals Inc (ARWR) as of Mar 10 2026?

As of Mar 10 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a FCF Yield of 1.70%. This means that for every dollar of Arrowhead Pharmaceuticals Inc's market capitalization, the company generates 1.70 cents in free cash flow.

What is the current Forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Mar 10 2026?

As of Mar 10 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a Forward P/E ratio of -21.43. This means the market is willing to pay $-21.43 for every dollar of Arrowhead Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Mar 10 2026?

As of Mar 10 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a Forward P/S ratio of 22.22. This means the market is valuing ARWR at $22.22 for every dollar of expected revenue over the next 12 months.

ARWR Valuation